Vaibhav Londhe

Misoprostol versus Foley catheter insertion for induction of labor in pregnancies affected by fetal growth restriction.

To compare 25 μg of vaginal misoprostol with a Foley catheter for induction of labor (IOL) for fetal growth restriction.

Hydroureteronephrosis in women with pelvic organ prolapse: a prospective cohort study

Pelvic organ prolapses (POP) is protrusion of pelvic organs (bladder, uterus, rectum) through the vagina from its normal position. The prevalence of POP in the general population is about 37% which increases to 64.8% in older women. Among them at least 30% may require surgery. The reported prevalence of hydroureteronephrosis (HUN) in women with pelvic organ prolapse is 7-50%. However, the true prevalence still unclear due to lack of prospective studies on sufficiently large cohorts.

Prevalence of voiding and defecatory dysfunction in postmenopausal women with pelvic organ prolapse: a prospective observational study

Pelvic organ prolapse (POP), is defined by the international continence society as the the symptomatic descent of the anterior vaginal wall, the posterior vaginal wall, the apex of the vagina or the vaginal vault. Women with POP may presents with symptoms of urinary incontinence, fecal incontinence, voiding dysfunction, and defecatory dysfunction, this interrelated group of conditions collectively describe as “Disorders of the Pelvic Floor”. This study aims to understand the prevalence and relationship between pelvic organ prolapse and voiding dysfunction and defecatory dysfunction. The available outcome of these measures can be used by clinicians and researchers to assess the functional outcomes of prolapse and its treatment on patients with an emphasis on symptom and quality-of-life assessment. ABSTRACT

Impact of premature ovarian insufficiency on cardiovascular health

Hypergonadotropic hypogonadism before the age of forty affects 1-2% of women. It occurs in 1 in 10,000 women by 20years, 1 in 1000 women by 30 years and reaches 1 in 100 by 40 years. ESHRE (European Society for Human Reproduction and Embryology) 2016 recommends the following diagnostic criteria for premature ovarian insufficiency (POI): (a) oligo/amenorrhoea for at least 4 months, and (b) an elevated follicle stimulating hormone (FSH) >25IU/l on 2 occasions more than 4 weeks apart. POI needs greater attention in the wake of its increased morbidity. Minor morbidities includes mood swings, vasomotor symptoms, sexual dysfunction, lower urinary tract symptoms and musculoskeletal issues. But in the long run they tend to develop life threatening issues like osteoporotic fractures and coronary artery disease.